Opthea To Present at Upcoming Investor Conferences

Rhea-AI Summary

Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company, announced CEO Dr. Megan Baldwin will present at two investor conferences in May 2022. The events include the Citi Biopharma Virtual Co-Panel Day on May 18, 2022, at 4:30 pm ET and the H.C. Wainwright Annual Global Life Sciences Conference on May 24, 2022, at 7:00 am ET. Both presentations will be available on the Investors page of Opthea's website for 90 days. Opthea focuses on developing therapies for retinal diseases, with its lead candidate OPT-302 in pivotal Phase 3 trials.

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at upcoming investor conferences in May.

Citi Biopharma Virtual Co-Panel Day
Date: Wednesday, May 18, 2022 4:30 pm ET (6:30 am AET)

H.C. Wainwright Annual Global Life Sciences Conference
Date: Tuesday, May 24, 2022 7:00 am ET (9:00 pm AET)

The Citi presentation will be available beginning Wednesday, May 18, at 4:30 pm ET (6:30 am AET), and the H.C. Wainwright presentation will be available beginning Tuesday, May 24, 2022 7:00 am ET (9:00 pm AET). Both presentations may be accessed for 90 days on the Investors page of the Opthea website at https://www.opthea.com/presentations/.

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Inherent risks of Investment in Biotechnology Companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialization and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specializing in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.

Authorized for release to ASX by Megan Baldwin, CEO & Managing Director

Company & Media Enquiries:
U.S.A. & International: Sam Martin Argot Partners Tel: +1 212-600-1902 opthea@argotpartners.com	Australia: Rudi Michelson Monsoon Communications Tel: +61 (0) 3 9620 3333
Media: Silvana Guerci-Lena NorthStream Global Partners Tel: +1 973-509-4671 silvana@nsgpllc.com

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399 Email: info@opthea.com Web: www.opthea.com

FAQ

When will Opthea Limited present at the Citi Biopharma Virtual Co-Panel Day?

Opthea Limited will present at the Citi Biopharma Virtual Co-Panel Day on May 18, 2022, at 4:30 pm ET.

What is the date of the H.C. Wainwright Annual Global Life Sciences Conference for Opthea?

The H.C. Wainwright Annual Global Life Sciences Conference for Opthea is scheduled for May 24, 2022, at 7:00 am ET.

Where can I access Opthea's conference presentations?

Both presentations can be accessed on the Investors page of Opthea's website for 90 days after the events.

What is the focus of Opthea's clinical development?

Opthea is focused on developing therapies for progressive retinal diseases, including wet age-related macular degeneration and diabetic macular edema.

What is the status of OPT-302 in Opthea's pipeline?

OPT-302 is currently in pivotal Phase 3 clinical trials.